Novartis CEO: We’re moving toward filing Covid drug from Molecular Partners with FDA


Novartis CEO Vas Narasimhan sits down with CNBC’s Meg Tirrell and the ‘Squawk on the Street’ team to discuss the company’s latest Covid-19 treatment, which it licensed from Molecular Partners.

See also  Trump sticks to rallies as COVID-19 roars back